Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)の価格はいくらですか

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)の価格は$4.64です

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)の時価総額は何ですか

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)の時価総額は$5.17Bです

Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) の収益

Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.

年	収益	変化
提供された日付のデータは十分ではありません。

年

収益

変化

提供された日付のデータは十分ではありません。

企業	収益	収益の差	国
Intuitive Surgical, Inc. ISRG.US	$11.03B	-	US
EssilorLuxottica S.A. EL.PA	$34.74B	-	FR
HOYA Corporation 7741.T	-	-	JP
Becton, Dickinson and Company BDX.US	$20.84B	-	US
Alcon Inc. ALC.SW	-	-	CH

企業

収益

収益の差

国